Prevalence and Determinants of Female Sexual Dysfunction, and Its Association With Neurotrophic Biomarkers in Gynaecological Cancer Survivors: A Cross-Sectional Study
Open Access
- 1 June 2026
- journal article
- research article
- Published by SAGE Publications in Cancer Control
- Vol. 33
Abstract
Introduction: Female sexual dysfunction (FSD) in any gynaecological cancer survivor is one aspect of female functioning that is neglected in survivorship care. Therefore, their actual prevalence is far from known to the treating physician. This study aimed to evaluate the prevalence of sexual dysfunction in gynaecological cancer survivors, determine its risk factors, and correlate sexual dysfunction with serum neurotropic factors. Methods: This was a cross-sectional, observational study among 200 gynaecological cancer survivors who are sexually active, conducted in the gynaecological cancer clinic at a tertiary care centre. Sexual function was assessed using the Hindi-validated Female Sexual Function Index (FSFI), and serum brain-derived neurotrophic factor (BDNF), substance P, and neuropeptide Y (NPY) were measured by ELISA. The correlation between these biomarkers, with domains and subdomains of the female sexual function index, was explored. Results: In this cohort of 200 gynaecological cancer survivors, 189 (94.5%) women had FSD (FSFI <26.55). Age was the only independent clinical predictor of FSD in multivariable analysis (p = 0.02), while cancer site, stage, treatment modality, and menopausal status were not significant in this cohort. Overall biomarker levels did not differ between women with and without FSD. However, subdomain analysis showed high dysfunction rates in lubrication, orgasm, pain, and arousal, with significant biomarker differences for substance P and NPY in several dysfunctional subdomains. Conclusions: FSD was highly prevalent in gynaecological cancer survivors. While overall biomarker differences were not significant, subdomain-specific associations suggest that substance P and NPY may have a role in domain-level sexual dysfunction and merit further study.Keywords
Funding Information
- All-India Institute of Medical Sciences (AC-37A)
This publication has 37 references indexed in Scilit:
- Female sexual function in long-term cervical cancer survivors compared with healthy women and women affected by benign gynecological disordersEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2024
- A survey of female sexual dysfunction in gynaecological cancer survivors: A case–control studyClínica E Investigación En Ginecología Y Obstetricia, 2023
- Gynaecological Oncology in India: Past, Present and FutureIndian Journal of Surgical Oncology, 2022
- Psychosexual health in gynecologic cancerInternational Journal of Gynecology & Obstetrics, 2018
- Neuropeptide Y: A stressful reviewNeuropeptides, 2016
- Evaluation of Sexual Dysfunction and Affecting Factors in Turkish Women with Gynecological CancerSexuality and Disability, 2015
- Changes in supportive care needs after first‐line treatment for ovarian cancer: identifying care priorities and risk factors for future unmet needsPsycho-Oncology, 2012
- Neuronal pathways linking substance P to drug addiction and stressBrain Research, 2010
- The role of substance P in stress and anxiety responsesAmino Acids, 2006
- Sexual functioning morbidity among cancer survivors. Current status and future research directionsCancer, 1985